Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

1.03USD
22 Mar 2017
Change (% chg)

$0.04 (+4.04%)
Prev Close
$0.99
Open
$1.00
Day's High
$1.07
Day's Low
$0.95
Volume
824,690
Avg. Vol
68,529
52-wk High
$3.00
52-wk Low
$0.51

PTIE.OQ

Chart for PTIE.OQ

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.03
Market Cap(Mil.): $45.68
Shares Outstanding(Mil.): 46.14
Dividend: --
Yield (%): --

Financials

  PTIE.OQ Industry Sector
P/E (TTM): -- 48.48 30.07
EPS (TTM): -0.33 -- --
ROI: -61.87 -2.48 13.05
ROE: -61.87 5.24 14.20

BRIEF-Pain Therapeutics announces positive regulatory guidance for Remoxy ER

* Pain Therapeutics announces positive regulatory guidance for Remoxy ER

Mar 20 2017

BRIEF-Pain Therapeutics reports qtrly loss per share $0.06

* Pain Therapeutics - in first two quarters of 2017, company expects its quarterly net cash burn rate will range from $2.0 million to $2.5 million Source text for Eikon: Further company coverage:

Feb 17 2017

BRIEF-Pain Therapeutics announces resignation of Peter Roddy as CFO

* On Feb 14, 2017, Peter Roddy resigned, effective March 9, 2017, as vice president, chief financial officer Source text for Eikon: Further company coverage:

Feb 17 2017

BRIEF-Pain Therapeutics Q3 loss per share $0.08

* Pain Therapeutics Inc- "we continue to evaluate comments recently raised by FDA with regards to remoxy"

Oct 20 2016

BRIEF-Pain Therapeutics CRL informs that REMOXY ER cannot be approved in its present form

* CRL informs that remoxy er cannot be approved in its present form

Sep 26 2016

More From Around the Web

Competitors

Earnings vs. Estimates